Last reviewed · How we verify
DMPA 104
At a glance
| Generic name | DMPA 104 |
|---|---|
| Also known as | depo-subQ provera 104® (104mg/0.65mL, sub-cutaneous) |
| Sponsor | FHI 360 |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Impact of Contraceptives on Cervico-Vaginal Mucosa (PHASE4)
- Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood (PHASE4)
- Study of Self or Clinic Administration of DepoProvera (NA)
- Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods (PHASE1)
- Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis (PHASE2)
- Lower Dose Depo Provera® Contraceptive Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMPA 104 CI brief — competitive landscape report
- DMPA 104 updates RSS · CI watch RSS
- FHI 360 portfolio CI